Safety and efficacy of uninterrupted treatment with edoxaban or warfarin during the peri-procedural period of catheter ablation for atrial fibrillation.
atrial fibrillation
catheter ablation
edoxaban
uninterrupted anticoagulation
warfarin
Journal
Journal of arrhythmia
ISSN: 1880-4276
Titre abrégé: J Arrhythm
Pays: Japan
ID NLM: 101263026
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
07
01
2020
revised:
22
03
2020
accepted:
06
04
2020
entrez:
13
8
2020
pubmed:
13
8
2020
medline:
13
8
2020
Statut:
epublish
Résumé
The real-world safety and efficacy of uninterrupted anticoagulation treatment with edoxaban (EDX) or warfarin (WFR) during the peri-procedural period of catheter ablation (CA) for atrial fibrillation (AF) are yet to be investigated. We conducted a two-center experience, observational study to retrospectively investigate consecutive patients who underwent CA for AF and received EDX or WFR. We examined the incidence of thromboembolic and bleeding complications during the peri-procedural period. The EDX and WFR groups included 153 and 103 patients, respectively (total: 256 patients). Demise or thromboembolic events did not occur in either of the groups. The incidence of major bleeding in the EDX and WFR groups was 0.7% and 2.9%, respectively. The total incidence of major/minor bleeding in the EDX and WFR groups was 7.8% and 8.7%, respectively. Of note, the incidence of bleeding complications in the uninterrupted WFR strategy group was markedly high in patients with an estimated glomerular filtration rate (eGFR) <30 (75%) or a HAS-BLED score ≥3 (60%). Patients with eGFR ≥30 and a HAS-BLED score ≤2 had a lower incidence of bleeding (<10%), regardless of the administered anticoagulation drug (EDX or WFR). This study confirmed the safety and efficacy of uninterrupted anticoagulation therapy using EDX or WFR in real-world patients undergoing CA for AF. Patients with severely impaired renal function and/or a higher bleeding risk during uninterrupted therapy with WFR were at a prominent risk of bleeding. Therefore, particular attention should be paid in the treatment of these patients.
Sections du résumé
BACKGROUND
BACKGROUND
The real-world safety and efficacy of uninterrupted anticoagulation treatment with edoxaban (EDX) or warfarin (WFR) during the peri-procedural period of catheter ablation (CA) for atrial fibrillation (AF) are yet to be investigated.
METHODS
METHODS
We conducted a two-center experience, observational study to retrospectively investigate consecutive patients who underwent CA for AF and received EDX or WFR. We examined the incidence of thromboembolic and bleeding complications during the peri-procedural period.
RESULTS
RESULTS
The EDX and WFR groups included 153 and 103 patients, respectively (total: 256 patients). Demise or thromboembolic events did not occur in either of the groups. The incidence of major bleeding in the EDX and WFR groups was 0.7% and 2.9%, respectively. The total incidence of major/minor bleeding in the EDX and WFR groups was 7.8% and 8.7%, respectively. Of note, the incidence of bleeding complications in the uninterrupted WFR strategy group was markedly high in patients with an estimated glomerular filtration rate (eGFR) <30 (75%) or a HAS-BLED score ≥3 (60%). Patients with eGFR ≥30 and a HAS-BLED score ≤2 had a lower incidence of bleeding (<10%), regardless of the administered anticoagulation drug (EDX or WFR).
CONCLUSIONS
CONCLUSIONS
This study confirmed the safety and efficacy of uninterrupted anticoagulation therapy using EDX or WFR in real-world patients undergoing CA for AF. Patients with severely impaired renal function and/or a higher bleeding risk during uninterrupted therapy with WFR were at a prominent risk of bleeding. Therefore, particular attention should be paid in the treatment of these patients.
Identifiants
pubmed: 32782633
doi: 10.1002/joa3.12351
pii: JOA312351
pmc: PMC7411202
doi:
Types de publication
Journal Article
Langues
eng
Pagination
634-641Informations de copyright
© 2020 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.
Déclaration de conflit d'intérêts
All authors have no conflict of interest relevant to the topic of this manuscript.
Références
Intern Med. 2015;54(10):1167-73
pubmed: 25986252
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
Pacing Clin Electrophysiol. 2015 Feb;38(2):155-63
pubmed: 25487164
Circulation. 2014 Jun 24;129(25):2638-44
pubmed: 24744272
Stroke. 1991 Aug;22(8):983-8
pubmed: 1866765
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Clin Drug Investig. 2016 Oct;36(10):837-48
pubmed: 27389243
J Cardiovasc Electrophysiol. 2018 Jun;29(6):835-843
pubmed: 29533476
Eur Heart J. 2019 Sep 21;40(36):3013-3021
pubmed: 30976787
Ann Intern Med. 2007 Jun 19;146(12):857-67
pubmed: 17577005
Intern Med. 2001 Dec;40(12):1183-8
pubmed: 11813841
Circ Arrhythm Electrophysiol. 2010 Feb;3(1):32-8
pubmed: 19995881
Circ J. 2017 Aug 25;81(9):1278-1285
pubmed: 28428449
Eur Heart J. 2015 Jul 21;36(28):1805-11
pubmed: 25975659
Circ J. 2019 Sep 25;83(10):2017-2024
pubmed: 31511436
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
Circ J. 2018 May 25;82(6):1552-1557
pubmed: 29657252
N Engl J Med. 2012 Aug 16;367(7):625-35
pubmed: 22894575
Am J Cardiol. 2017 Nov 1;120(9):1562-1567
pubmed: 28847595
N Engl J Med. 1998 Sep 3;339(10):659-66
pubmed: 9725923
Am J Cardiol. 2017 Apr 15;119(8):1229-1237
pubmed: 28219663
Int J Cardiol. 2009 Oct 2;137(2):102-7
pubmed: 18691774
Circ J. 2018 Jan 25;82(2):346-352
pubmed: 28954934
Circ J. 2014;78(8):1997-2021
pubmed: 24965079
JAMA. 2001 Jun 13;285(22):2864-70
pubmed: 11401607